In biotechnology, where scientific programmes often pivot as new data emerge, the ability to distinguish between commitment to an idea and commitment to a problem can determine the success or failure of a company. That is the central message from Philip Ashton-Rickardt, Managing Director and Chief Scientific Officer at BE Therapeutics, who has spent more than three decades navigating the uncertain terrain of academic research, biotech entrepreneurship, and R&D leadership.
Ashton-Rickardt’s career has included professorships at the University of Chicago and Imperial College London, founding Smith Therapeutics, serving as Chief Scientific Officer at Sigilon Therapeutics, advising companies through Flagship Pioneering, and helping build Halyard Therapeutics and BE Therapeutics. Across these roles, he has observed how easily a leader’s attachment to a hypothesis can become a liability. “You have to separate attachment to the idea from attachment to the problem,” Ashton-Rickardt said. “If the problem is important, there may be several ways to approach it.”
That distinction is particularly relevant in biotech, where a promising hypothesis at the start of a project may need to be adjusted, narrowed, or abandoned entirely as evidence accumulates. For Ashton-Rickardt, changing direction does not signal failure. “Flexibility is important because changing your approach is not necessarily an admission that you failed,” he said. “Sometimes it is evidence that you learned something.”
The implications for the biotech industry are significant. Companies that treat strategic shifts as defeats risk clinging to flawed programmes, wasting time and capital. Those that embrace flexibility may be better positioned to allocate resources toward approaches that actually address the underlying problem. This mindset can also influence how teams run experiments and how investors evaluate progress.
Ashton-Rickardt also highlights the difficulty of leading without projecting false certainty. Researchers, executives, and investors often need decisions before all questions are answered, creating pressure to sound more confident than the evidence justifies. He advocates being clear about what is known, what remains uncertain, and what would trigger a change in direction. “There is a difference between providing direction and pretending to know the future,” he said. “In biotech, there are simply too many unknowns.”
That transparency, he argues, can strengthen confidence rather than weaken it. When teams understand that new information is expected to shape decisions, they may be more willing to raise concerns, question assumptions, and share evidence that challenges the current plan. Such openness can make scientific organisations more adaptable at a time when new tools, data, and therapeutic approaches are rapidly changing what is possible.
Ashton-Rickardt’s perspective is shaped by a career that has repeatedly required him to enter unfamiliar territory. Raised in a working-class family in the UK, he worked his way through university and into academic science before leaving a long-established academic career to return to Boston and start a biotech company. He has since moved between startups, established biotech companies, research organisations, and investment-backed environments. Throughout those changes, he says curiosity has remained one of the most important qualities a leader can keep. “The people I enjoy working with tend to ask good questions, even when those questions make the project more complicated,” he said.
He also believes leaders should be willing to admit what they do not know. In his experience, someone who has thought deeply about an idea does not need to pretend it has no weaknesses. Instead, strong scientific thinking often shows up in the ability to explain what evidence would change a person’s mind.
Ashton-Rickardt’s current work remains focused on engineered cell therapies and approaches to treating neurological and other serious diseases. At BE Therapeutics, where he serves as Managing Director and Chief Scientific Officer, and at Halyard Therapeutics, where he is a co-founder and Chief Scientific Officer, his work continues to centre on translating complex scientific ideas into programmes that can move forward. That process, he says, requires conviction, but conviction has to remain connected to evidence. “The goal is not to prove that your first idea was right,” Ashton-Rickardt said. “The goal is to solve an important problem.”
For scientists and biotech leaders, that difference can shape everything from how teams design experiments to how companies decide where to invest time and resources. In an industry where uncertainty is the only constant, the willingness to change course may be the most valuable skill of all.
